Therapy Areas: AIDS & HIV
Nature Publishes Non-Human Primate Preclinical Viral Challenge Study of Single-shot Ad26 Vaccine that Protects Against SARS-CoV-2
31 July 2020 - - US-based research journal Nature has published the successful testing of a candidate vaccine in non-human primates, US-based in-vivo testing programmes developer Bioqual said.

A group of scientists, led by Beth Israel Deaconess Medical Center (BIDMC) immunologist Dan H. Barouch, MD, PhD, now report that a candidate COVID-19 vaccine developed at BIDMC in collaboration with Johnson and Johnson (NYSE: JNJ) raised neutralising antibodies and robustly protected non-human primates against SARS-CoV-2, the virus that causes COVID-19.

Bioqual has been engaged in development of in-vivo testing programs and has been extensively involved in research efforts to develop vaccines and therapies against emerging diseases including AIDS, Hepatitis, Zika, Chikungunya and many others.

The company is now focused on COVID-19 research and is positioned to play an important role in the development of successful vaccines and therapies against this epidemic.


Related Headlines